-transparent.png){kind=logo}
1. The fate in the pregnant New Zealand White rabbit of oral doses of four (14)C-labelled hydrolysis products of thalidomide, namely alpha-(o-carboxybenzamido)-glutarimide, 2-phthalimidoglutaramic acid, 2-phthalimidoglutaric acid and 2-(o-carboxybenzamido)glutaramic acid, administered on the 192nd hour of pregnancy has been studied. 2. About 60-95% of the administered (14)C of each compound appears in the urine in 58hr. and the remainder is found in the faeces and in the gut and its contents. 3. Radioactivity is present in the plasma, liver, kidney, brain, muscle, fat and embryo. 4. The (14)C-labelled substances in the plasma and embryo consist of the unchanged compounds and their further hydrolysis products. 5. Since the above four thalidomide hydrolysis products are found in the rabbit conceptus together with their further hydrolysis products after their oral administration to the pregnant rabbit, it appears that the teratogenic activity of thalidomide is due to the compound itself rather than to one or more of its hydrolysis products.
S Fabro, and
R L Smith, and
R T Williams
October 1965,
British journal of pharmacology and chemotherapy,
S Fabro, and
R L Smith, and
R T Williams
April 1973,
Experientia,
S Fabro, and
R L Smith, and
R T Williams
June 1964,
Pharmaceutica acta Helvetiae,
S Fabro, and
R L Smith, and
R T Williams
January 1970,
Mikrochimica acta,
S Fabro, and
R L Smith, and
R T Williams
October 1965,
British journal of pharmacology and chemotherapy,
S Fabro, and
R L Smith, and
R T Williams
April 1966,
British journal of experimental pathology,
S Fabro, and
R L Smith, and
R T Williams
October 1965,
Chemical & pharmaceutical bulletin,
S Fabro, and
R L Smith, and
R T Williams
January 1994,
Functional and developmental morphology,
S Fabro, and
R L Smith, and
R T Williams
July 2019,
Journal of medicinal chemistry,
